Disclosure Information

Safely Minimizing Opioid Use After Abdominal Cancer Surgery: Advice and Guidelines for Practicing Surgeons
July 20 | 6:00-7:00pm CDT
Chicago, IL 

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible company

The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships

Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.  Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.  ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity.  Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation. 

Speaker and Moderator Disclosures

Lesly Dossett, MD, MPH, FACS - Nothing to Disclose
Dr. Lesly Dossett is a surgical oncologist and division chief of surgical oncology at the University of Michigan, Ann Arbor. Dr. Dossett’s clinical focus is on breast cancer, melanoma, sarcoma, and complex gastrointestinal (GI) malignancies. She will be giving an overview of the opioid epidemic, the role surgeons have played, and evidence for overprescribing and persistent opioid use in early-stage cancer patients.

Naruhiko Ikoma, MD  - Nothing to Disclose
Dr. Naruhiko Ikoma is a surgical oncologist at the University of Texas MD Anderson Cancer Center in Houston. Dr. Ikoma specializes in minimally invasive surgery, gastric, and pancreas surgery. He will be discussing strategies to safely minimize opioid usage after minimally invasive cancer surgery. 

Cornelius A. Thiels, DO, MBA  - Nothing to Disclose
Dr. Cornelius A. Thiels is currently a surgical oncology fellow at Memorial Sloan Kettering Cancer Center in New York, NY, and is returning to Mayo Clinic in Rochester, MN, to join the division of hepatobiliary and pancreas surgery this summer. Dr. Thiels serves on the ACS Patient Education Opioid Workgroup and will discuss Mayo Clinic’s experience in safely minimizing opioid prescribing after abdominal cancer surgery.

Program Committee Disclosures

Lesly Dossett, MD, MPH, FACS  - Nothing to Disclose
Naruhiko Ikoma, MD  - Nothing to Disclose
Cornelius A. Thiels, DO, MBA  - Nothing to Disclose